To all:
As I posted yesterday, here comes more news for IMUL. Enjoy a happy trading tomorrow.
Monday January 27 5:34 PM EST
Immulogic Pharmaceutical Corp Allervax improves
allergies
WALTHAM, Mass., Jan 27 (Reuter) - ImmuLogic Pharmaceutical Corp said on Monday said
preliminary analyses of a 1996 trial showed the eight-dose 250 microgram group of Allervax
Ragweed product significantly improved patients' ragweed allergies.
It also significantly reduced medication use across the ragweed allergy season, ImmuLogic said.
"This trial, the first to evaluate the eight-dose 250 microgram regimen, produced very positive
results," said Joseph Marr, acting president and chief executive officer of ImmuLogic. The study
was a double-blind, placebo-controlled ragweed season trial, it said.
Marr said, "It successfully demonstrated efficacy, quantitated the clinical benefit through
comparison of the treated group to the observation group, and showed that the Allervax Ragweed
product had a significant impact on reducing medication use."
The company said it expected completion of a clinical development program for this product would
require similar results from a 1997 ragweed seasonal trial.
ImmuLogic is a biopharmaceutical company which aims to develop peptide therapeutics to treat
allergies, including cat and ragweed allergies, and autoimmune diseases such as multiple sclerosis. |
